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Use of an automated DNA analysis system (DARAS®) for sequence-specific
recognition of Neisseria meningitidis DNA
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Department of Microbiology & PHLS Laboratory, University Hospital, Nottingham, UK
Objective To combine use of the polymerase chain reaction (PCR) for rapid diagnosis of meningococcal
meningitis with a novel automated detection system for sequence-specific recognition of PCR products.
Methods DNA was extracted from cerebrospinal fluid (CSF) by a quick boil-lysis method, followed by PCR
with primers specific for Neisseria meningitidis. Sequence-specific recognition of N. meningitidis DNA was
performed with an automated DNA analysis system (DARAS®) and the data were compared with results
following agarose gel electrophoresis or conventional microbiological culture.
Results The DARAS® system had a sensitive detection limit of 102 meningococci/mL with spiked samples,
compared with a detection limit of 104 meningococci/mL following agarose gel electrophoresis. When the
system was used to examine 74 CSF samples, the 19 CSF samples positive for N. meningitidis by conventional
microbiological methods were also all positive in the DARAS® system and the 55 samples negative by DARAS®
for meningococci were also negative by conventional microbiological methods.
Conclusion The sensitivity and specificity of the DARAS® system makes it a useful tool for the diagnosis of
meningococcal meningitis. The system is user-friendly, requires minimal hands-on time and generates data in
an informative numerical format.
Keywords Meningitis, Neisseria meningitidis, DARAS®, polymerase chain reaction, sequence-specific detection
of DNA
Accepted 3 August 1999
Part of this work was presented as a poster at the 9th European Congress of Clinical Microbiology and
Infectious Diseases, Berlin, March 1999 (abstract P612).
Clin Microbiol Infect 2000: 6: 29–33
INTRODUCTION
Bacterial meningitis, particularly that associated with strains of
Neisseria meningitidis, remains an important health problem in
the UK and world-wide. An initial presumptive diagnosis of
meningitis is often made on the basis of clinical observations,
and this is then supported by microscopic examination of cer-
ebrospinal fluid (CSF) and, where possible, by culture of the
infecting organism from CSF or blood [1,2]. However,
this method is time-consuming (requiring 24–48 h for an
unequivocal result) and the recommended prehospitalization
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antibiotic treatment may reduce the chance of successful culture
[3]. The need for precise rapid identification of bacterial patho-
gens in cases of suspected meningitis has resulted in the devel-
opment of specific techniques based on the polymerase chain
reaction (PCR) to guide appropriate treatment and prophylaxis
[4–7]; indeed, PCR is now used routinely by the national
Meningitis Reference Unit in the UK for investigating pre-
sumed cases of bacterial meningitis [8] since its successful appli-
cation does not depend on the presence of viable organisms.
Specific PCR products can be detected following agarose gel
electrophoresis or in enzyme-linked immunosorbent assays
[5,6], but the need for these relatively time-consuming and
labour-intensive procedures has limited the introduction of this
successful technique into routine diagnostic laboratories. The
aim of the present study was to assess whether PCR for rapid
diagnosis of meningococcal meningitis could be used in con-
junction with a novel automated detection system (DARAS®;
Tepnel Life Sciences, Manchester, UK) [9] that combines the
amplification potential of PCR with sequence-specific capture
and colorimetric detection of PCR products.
30 Clinical Microbiology and Infection, Volume 6 Number 1, January 2000
METHODS
DARAS®
The DARAS® system is a robotic, computer-controlled instru-
ment that enables sequence confirmation of PCR products,
thereby eliminating the need for conventional gel-based sep-
aration and analysis methods. A customized DNA test system
is created by covalently amino-linking a target-specific internal
capture probe to chemically activated microbeads packed in
reaction columns. This is done in an automated process in
the DARAS® instrument that takes approximately 30 min to
complete. The customized reaction columns can then be used
immediately or stored for up to 12 months. During subsequent
detection experiments, biotinylated PCR product is heat-
denatured in the reaction columns and hybridizes to the coval-
ently linked capture probe at a specific annealing temperature.
Once the biotinylated target strand from a PCR product has
been captured, unbound contaminants, such as proteins,
enzymes, salts and noncomplementary DNA molecules, are
washed from the reaction columns. The captured DNA strand
is then detected by means of a standard biotin/streptavidin-
alkaline phosphatase conjugate reaction in which the bound
alkaline phosphatase catalyses the first step in a reaction pathway
leading to the production of a coloured product, formazan,
which can be measured photometrically at 492 nm. The
DARAS® instrument controls and automates all the stages
involved in the process, from covalent linkage of the capture
oligonucleotide through to detection of the coloured product.
Precise temperature control and liquid handling ensures that all
reactions and washes are performed under optimum conditions
in the reaction columns.
Oligonucleotides
These are listed in Table 1 and were custom-synthesized by PE
Biosystems (Warrington, UK). Primers P1 and P2 amplify a
specific 1.1 kb fragment of the N. meningitidis porA gene. The
specificity of these primers has been demonstrated previously
[4,6]. The internal capture probe Int3 was designed following
computer analysis of the porA gene sequence [4] to specifically
capture the PCR product produced following amplification
with primers P1 and P2. Int3 was synthesized with an NH2
Table 1 Oligonucleotides used in the study
Primer/probe DNA sequence
Primer P1 5?-gCggCCgTTgCCgATgTCAgCC
Primer P2 5?-biotin-gCggCATTAATTTgAgTgTAgTTgCC
Capture probe Int3 5?-NH2-gTggAgCgAgCgTCAggTAAA
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group at the 5? end to allow covalent linkage to the chemically
activated microbeads packed in the reaction columns.
Bacteria and clinical samples
Initial sensitivity experiments were performed with sterile dis-
tilled water or pooled sterile CSF spiked with dilutions of a
known suspension of N. meningitidis strain SD, B:15:P1. CSF
samples that had been sent to the diagnostic microbiology lab-
oratories at University Hospital, Nottingham, UK from 74
patients suspected of suffering from meningococcal meningitis
were also included in the study.
DNA extraction and PCRs
Total DNA was released from all CSF samples by heating
50 mL portions in 500 mL microfuge tubes at 95 °C for 15 min,
followed by centrifugation at 12 000 g for 1 min. PCRs were
performed with Ready-To-Go PCR beads (Amersham Phar-
macia Biotech, Little Chalfont, UK) in final 25 mL volumes
containing 5 mL of crude heated CSF extract and 2.5 pmol each
of primers P1 and P2. Each PCR comprised 40 cycles of 2 min
at 95 °C, 2 min at 55 °C and 2 min at 72 °C, followed by
6 min at 72 °C. PCR products were examined by conventional
agarose gel electrophoresis, following staining with ethidium
bromide [10], and in the DARAS® instrument, and the results
obtained were compared with those obtained by conventional
culture techniques [1,2] in the diagnostic microbiology labora-
tory.
Figure 1 Sensitivity of detection of specific PCR products by agarose
gel electrophoresis and staining with ethidium bromide. Each lane
contained the products of an identical PCR (as described in Methods)
derived from sterile distilled water spiked with dilutions of a known
suspension of N. meningitidis strain SD, B:15:P1. Lane A, 108
CFU/mL; lane B, 107 CFU/mL; lane C, 106 CFU/mL; lane D, 105 CFU/mL;
lane E, 104 cfu/mL; lane F, 103 CFU/mL.
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DARAS® reactions
Covalent binding of the capture probe Int3 to the microbeads
in the reaction columns was performed as recommended by
the manufacturer (Tepnel Life Sciences). Following completion
of the PCRs, 10 mL of biotinylated (via the P2 primer) PCR
end product was diluted 1 : 10 in DARAS® sample buffer and
70 mL was loaded into GeNunc microwells (Gibco BRL, Pais-
ley, UK) in the DARAS® instrument. During the automated
DARAS® procedure, the biotinylated strand of the N. men-
ingitidis-specific PCR product was captured by hybridization
to the Int3 capture probe linked to the microbeads. Once
immobilized, the biotinylated fragment was detected in the
DARAS® instrument using a streptavidin-alkaline phosphatase
signal generation system and on-line measurement of absorb-
ance at 492 nm. The entire procedure takes approximately
45 min to complete. All manipulations and reactions were auto-
mated and performed in the DARAS® instrument with the
software, protocols and reagents supplied by the manufacturer.
A ‘positive’ result was recorded when a sample generated an
0·070
SL
O
PE
 (A
bs
49
2 n
m/
mi
n)
0·050
0·000
0·030
0·040
0·060
1
0·010
0·020
122 3 4 5 6 7 8 9 10 11
Samples
–0·010
Figure 2 Sensitivity and reproducibility of detection of specific PCR products in the DARAS® instrument. The samples were derived from a
single pool of sterile CSF spiked with dilutions of a known suspension of N. meningitidis strain SD, B:15:P1. Samples 1–4 contained 102
CFU/mL; samples 5–8 contained 103 CFU/mL; samples 9–12 were negative nonspiked controls from the same pool of CSF.
© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 29–33
absorbance value that was at least four-fold greater than that
generated by the negative control analysed in the same
DARAS® run.
RESULTS
Spiked samples
Initial results obtained with sterile distilled water spiked with
dilutions of a known suspension of N. meningitidis demonstrated
that the PCR method, followed by conventional agarose gel
electrophoresis and staining with ethidium bromide, could
detect a minimum of 104 colony-forming units (CFU)/mL in
the original sample (Figure 1), equivalent to 50 CFU/5 mL of
heat-treated extract. Some minor variations in signal generation
were observed between runs with the DARAS® system, and
for this reason it was considered necessary always to interpret
the results in comparison with a negative control included in
every DARAS® run, with a ‘positive’ result being defined as an
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absorbance value at least four-fold greater than that generated
by the negative control. On this basis, the DARAS® system
was more sensitive and was capable of reproducibly dis-
tinguishing 102 CFU/mL in the original sample (equivalent to
1 CFU/5 mL of heat-treated extract) from the background
signal associated with negative controls. The fact that 1
CFU/5 mL of heat-treated extract could be detected was indica-
tive of the presence of nonviable meningococci in the original
suspension. Results obtained with spiked sterile distilled water
and spiked pooled sterile CSF were identical. Figure 2 illustrates
the results obtained with a single pool of sterile CSF spiked
with 102 or 103 CFU of meningococci/mL, compared with
unspiked sterile CSF from the same pool.
Clinical samples
When the PCR method was used to examine 74 CSF samples
taken from patients suspected of suffering from meningococcal
meningitis, the 19 samples defined as positive in the DARAS®
instrument were also positive for N. meningitidis by agarose gel
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Figure 3 Examples of positive and negative results obtained with CSF samples from patients suspected of suffering from meningococcal
meningitis. Samples 1–10, patient CSF specimens; sample 11, negative control (pooled sterile CSF); sample 12, positive control (pooled sterile
CSF spiked with N. meningitidis strain SD, B:15:P1/mL 103 CFU.
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electrophoresis of PCR products and by conventional micro-
biological methods. The 55 samples defined as negative in
the DARAS® instrument were also negative by agarose gel
electrophoresis and by conventional microbiological culture.
Figure 3 provides an illustration of the results obtained.
DISCUSSION
An initial presumptive diagnosis of bacterial meningitis is often
made on the basis of clinical observations, supported sub-
sequently by culture of the infecting organism from CSF or
blood. Confirmation of the diagnosis can be made from CSF
in approximately 90% of patients [1], but the culture-based
method is time consuming and may be unsuccessful, particularly
with blood samples [3], because of presampling antibiotic treat-
ment. The use of PCR for detection of meningococci [4–7]
does not depend on culture and the introduction of PCR for
routine use by the national reference laboratory in the UK has
increased the number of laboratory-confirmed cases of men-
ingococcal disease by 35% in the first year [8]. The specific
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meningococcal PCR products are normally detected on the
basis of their size following agarose gel electrophoresis, but the
need for electrophoresis has limited the introduction of the
PCR technique into routine diagnostic laboratories and the
analytical process may be complicated by the presence of other
nonspecific PCR products of similar size. Thus, in order to
obtain an unequivocal result, there is a need for a rapid, simple
and user-friendly method of sequence-based recognition of
specific PCR products.
In an attempt to address this problem, the present study
assessed the use of a specific PCR for N. meningitidis in com-
bination with analysis of amplicons in the innovative DARAS®
instrument designed to provide automated sequence-specific
detection of PCR products. Manipulation and detection of
PCR products by the automated technology seemed to provide
accurate detection at lower DNA input levels than could be
detected on agarose gels, while at the same time eliminating
the technical problems associated with interpretation of con-
ventional gel-based separation and analysis methods. The dis-
posable microbead reaction columns contained in the
instrument can be customized to capture any PCR product of
interest, giving the possibility of quite complex DNA manipu-
lations and secondary indirect detection protocols. However,
the direct primary detection of biotin-labelled PCR fragments
used in the present study was successful in demonstrating the
sensitivity and specificity of the DARAS® system. Some minor
run-to-run variations in signal generation were observed but,
overall, it was concluded that the system was a useful tool for
the diagnosis of meningococcal meningitis. The instrument was
user-friendly, required minimal hands-on time and generated
data in an informative numerical format. The fully automated
DARAS® instrument has a capital cost of UK £15 000 (US
$22 500), with a total consumables cost per specimen of
approximately UK £4 (US $6). The main technical limitation
of the first generation DARAS® instrument seemed to be the
small number of samples (12) that could be loaded per run,
although a test completion time of approximately 45 min with
a preprogrammed protocol means that several batches of sam-
ples can be analysed within a single working day.
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